BeiGene News
- March 25, 2020BeiGene Announces Supply Update for ABRAXANE® in China
BeiGene Announces Supply Update for ABRAXANE® in China
- March 2, 2020BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results
- February 27, 2020MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
- February 25, 2020BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference
BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference
- January 21, 2020BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
- January 13, 2020EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China
- BeiGene Facts
- Founded 2010
- Listings NASDAQ: BGNE
HKEX: 06160 - Internally Developed
Clinical Candidates 7 - Marketed
Products
in China 4 - Approved
products
in the U.S.1 - Global Team 3500+
2010
- BeiGene was founded as a research and development company
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- 50+ ongoing or planned clinical trials
2019
- Received first FDA approval for BRUKINSA™ (zanubrutinib)
- Received first approval for tislelizumab in China
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.